Claims
- 1-38. (cancelled)
- 39: A method for the treatment of a HCV infection in a host in need thereof comprising administering an effective treatment amount of a β-D-2′-fluoronucleoside, or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.
- 40: The method of claim 39, wherein the β-D-2′-fluoronucleoside has a pyrimidine base.
- 41: The method of claim 40, wherein the pyrimidine base is selected from the group consisting of thymine, uracil, 5-halouracil, 5-fluorouracil, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-aza-pyrimidine, 6-azacytosine, 2- and/or 4-mercaptopyrmidine, C5-alkylpyrimidine, C5-benzylpyrimidine, C5-halopyrimidine, C5-vinylpyrimidine, C5-acetylenic pyrimidine, C5-acyl pyrimidine, C5-hydroxyalkyl purine, C5-amidopyrimidine, C5-cyanopyrimidine, C5-nitropyrimidine, and C5-aminopyrimidine.
- 42: The method of claim 40, wherein the pyrimidine base is thymine.
- 43: The method of claim 40, wherein the pyrimidine base is uracil.
- 44: The method of claim 40, wherein the pyrimidine base is 5-halouracil.
- 45: The method of claim 40, wherein the pyrimidine base is cytosine.
- 46: The method of claim 40, wherein the pyrimidine base is 5-fluorocytosine.
- 47: The method of claim 39, wherein the β-D-2′-fluoronucleoside has a purine base.
- 48: The method of claim 47, wherein the purine base is selected from the group consisting of N6-alkylpurine, N6-acylpurine (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N6-benzylpurine, N6-halopurine, N6-vinylpurine, N6-acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-thioalkyl purine, N2-alkylpurines, N2-alkyl-6-thiopurines, N2-alkylpurine, N2-alkyl-6-thiopurine, 5-azacytidinyl, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine.
- 49: The method of claim 39, wherein the β-D-2′-fluoronucleoside has a triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, or pyrazolopyrimidinyl base.
- 50: The method of claim 39, wherein the β-D-2′-fluoronucleoside is in substantially pure form.
- 51: The method of claim 39, wherein the β-D-2′-fluoronucleoside is at least 90% by weight of the β-D-isomer.
- 52: The method of claim 39, wherein the β-D-2′-fluoronucleoside is at least 95% by weight of the β-D-isomer.
- 53: The method of claim 39, wherein the β-D-2′-fluoronucleoside is administered in the form of a dosage unit.
- 54: The method of claim 53, wherein the dosage unit contains 50-1000 mg of the compound.
- 55: The method of claim 53, wherein the dosage unit is in the form of a tablet or capsule.
- 56: The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for oral delivery.
- 57: The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for intravenous delivery.
- 58: The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery.
- 59: The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for intradermal delivery.
- 60: The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous delivery.
- 61: The method of claim 39, wherein the pharmaceutically acceptable carrier is suitable for topical delivery.
- 62: The method of any one of claims 39-49, wherein the host is a human.
Parent Case Info
[0001] This application claims priority to U.S. provisional patent application Nos. 60/075,893, filed on Feb. 25, 1998 and 60/080,569, filed on Apr. 3, 1998.
Government Interests
[0002] The invention described herein was made with Government support under grant number AI32351 awarded by the National Institutes of Health. The United States Government has certain rights to this invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60075893 |
Feb 1998 |
US |
|
60080569 |
Apr 1998 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
10061128 |
Jan 2002 |
US |
Child |
10796529 |
Mar 2004 |
US |
Parent |
09257130 |
Feb 1999 |
US |
Child |
10061128 |
Jan 2002 |
US |